Article
Oncology
Chrisann Kyi, Ekaterina Doubrovina, Qin Zhou, Sara Kravetz, Alexia Iasonos, Carol Aghajanian, Paul Sabbatini, David Spriggs, Richard J. O'Reilly, Roisin E. O'Cearbhaill
Summary: This study demonstrated the safety of using WT1-sensitized T cells for treating patients with recurrent ovarian, primary peritoneal, and fallopian tube carcinomas, but no therapeutic activity was observed at the low doses evaluated.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Florian Maerkl, Mohamed-Reda Benmebarek, Julius Keyl, Bruno L. Cadilha, Martina Geiger, Clara Karches, Hannah Obeck, Melanie Schwerdtfeger, Stefanos Michaelides, Daria Briukhovetska, Sophia Stock, Jakob Jobst, Philipp Jie Mueller, Lina Majed, Matthias Seifert, Anna-Kristina Kluever, Theo Lorenzini, Ruth Gruenmeier, Moritz Thomas, Adrian Gottschlich, Richard Klaus, Carsten Marr, Michael von Bergwelt-Baildon, Simon Rothenfusser, Mitchell P. Levesque, Markus Vincent Heppt, Stefan Endres, Christian Klein, Sebastian Kobold
Summary: Melanoma is an immune sensitive disease, and immune check point blockade has shown activity. However, TIL therapy after ICB failure has shown promising efficacy, indicating the potential of cellular therapies. To overcome limitations of TIL treatment, a controlled adoptive cell therapy approach using synthetic agonistic receptors and bispecific antibodies targeting melanoma-associated antigens is proposed.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Audrey Moatti, Anais Debesset, Caroline Pilon, Asma Beldi-Ferchiou, Mathieu Leclerc, Rabah Redjoul, Frederic Charlotte, Nhu Hanh To, Adeline Bak, Yazid Belkacemi, Benoit Laurent Salomon, Fadi Issa, David Michonneau, Sebastien Maury, Jose Laurent Cohen, Allan Thiolat
Summary: This study reveals the potential of targeting TNFR2 to enhance anti-tumor responses and treat relapse of blood malignancies. The researchers also found that TNFR2 is over-expressed in Tregs from healthy donors and patients with leukemia relapse or GVHD. These findings provide new perspectives for the development of immunotherapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Pharmacology & Pharmacy
Amelia C. McCue, Zhiyuan Yao, Brian Kuhlman
Summary: Protein engineering has played a significant role in T cell immunotherapy, particularly in CAR T cell therapy. Current gene editing techniques have limitations in controlling CART cell activity, but CARs engineered to bind adapter molecules provide an alternative control method. This adapter-mediated approach enables flexible interaction between CART cells and target cells, overcoming the specificity limitations of traditional CAR T cells.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Article
Oncology
Yi-Chiu Kuo, Cheng-Fu Kuo, Kurt Jenkins, Alfur Fu-Hsin Hung, Wen-Chung Chang, Miso Park, Brenda Aguilar, Renate Starr, Jonathan Hibbard, Christine Brown, John C. Williams
Summary: The use of universal CAR T cells shows promise in improving the efficacy of cancer treatment and has broad potential applications.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemical Research Methods
Cuilin Zhang, Qiuyu Zhuang, Jingfeng Liu, Xiaolong Liu
Summary: Synthetic biology is an interdisciplinary research area that uses engineering principles to design and construct biological systems for practical applications. Chimeric antigen receptor (CAR) T cells, as one of the most successful clinical applications of synthetic biology, have shown tremendous success in treating blood malignancies. However, there are still limitations to CAR T cell therapy, hence the need for innovative CAR design becomes urgent.
ACS SYNTHETIC BIOLOGY
(2022)
Article
Oncology
Jitendra Kumar, Ritesh Kumar, Amir Kumar Singh, Elviche L. Tsakem, Mahesh Kathania, Matthew J. Riese, Arianne L. Theiss, Marco L. Davila, K. Venuprasad
Summary: The study identified Cbl-b as a potential target for overcoming exhausted CAR T-cell function in solid tumors. Inhibition of Cbl-b restored effector function of exhausted T cells. Depletion of Cbl-b enhanced CAR T-cell efficacy in reducing tumor growth, decreasing exhausted T cells, and increasing effector cytokine expression.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Chemistry, Physical
Yongxin Zhang, Hao Fu, Jiajing Chen, Linlin Xu, Yingli An, Rujiang Ma, Chunlei Zhu, Yang Liu, Feihe Ma, Linqi Shi
Summary: This article introduces a holdase/foldase mimetic nanochaperone (H/F-nChap) for co-delivery of multiple mAbs, which significantly improves cancer immunotherapy. The nanochaperone exhibits holdase activity in blood and normal tissues, protecting mAbs and reducing side effects. In the tumor microenvironment, it switches to foldase activity, enhancing immune activation.
Article
Oncology
Samantha M. Fix, Marie-Andree Forget, Donastas Sakellariou-Thompson, Yunfei Wang, Tamara M. Griffiths, Minjung Lee, Cara L. Haymaker, Ana Lucia Dominguez, Rafet Basar, Christopher Reyes, Sanjay Kumar, Larissa A. Meyer, Patrick Hwu, Chantale Bernatchez, Amir A. Jazaeri
Summary: In this study, we optimized CRISPR/Cas9-mediated knockout of TGF-beta receptor 2 (TGFBR2) in patient-derived ovarian cancer TIL. TGFBR2 knockout TIL showed resistance to immunosuppression and improved cytotoxicity. This lays the groundwork for clinical translation of CRISPR-modified TIL for the treatment of ovarian cancer and other solid cancers.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Julia Karbach, Dragan Kiselicki, Kathrin Brand, Claudia Wahle, Evgueni Sinelnikov, Dirk Gustavus, Hans Hoffmeister, Hans-Bernd Prisack, Akin Atmaca, Elke Jaeger
Summary: Adoptive transfer of autologous tumor-specific lymphocytes in conjunction with IL-2 and immune-checkpoint blockade led to complete and durable tumor remission in a patient with metastatic hormone-refractory NY-ESO-1 expressing prostate cancer. The treatment resulted in a decrease of tumor-driven NY-ESO-1 serum antibody and prostate-specific antigen, demonstrating the effectiveness of this method for advanced malignancies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Editorial Material
Biochemical Research Methods
Michael B. Sheets, Joshua T. Atkinson, Mark P. Styczynski, Emily R. Aurand
Summary: As engineering biology continues to have increasing impacts, it is crucial to introduce the field early on in an accessible manner. However, teaching engineering biology faces challenges such as limited representation in widely used scientific textbooks or curricula, as well as its interdisciplinary nature. To address this, we have developed an adaptable curriculum module that provides a versatile slide deck designed by engineering biology experts to cover the fundamental principles and applications of the field. Free and accessible through a public website, this module can be used independently or integrated into existing curricula, aiming to enhance the ease of teaching current engineering biology topics and promote public engagement with the field.
ACS SYNTHETIC BIOLOGY
(2023)
Review
Biotechnology & Applied Microbiology
Javad Aminian-Dehkordi, Shadi Rahimi, Mehdi Golzar-Ahmadi, Amritpal Singh, Javiera Lopez, Rodrigo Ledesma-Amaro, Ivan Mijakovic
Summary: Synthetic biology offers new solutions for environmental protection by developing remediation systems using genetically engineered microbes and plants, and utilizing computational methods for design and application to detect and respond to specific pollutants.
BIOTECHNOLOGY ADVANCES
(2023)
Article
Oncology
Ingunn M. Stromnes, Ayaka Hulbert, Meagan R. Rollins, Ryan S. Basom, Jeffrey Delrow, Patrick Bonson, Adam L. Burrack, Sunil R. Hingorani, Philip D. Greenberg
Summary: This study investigates the role of immune checkpoints in mediating functional dysfunction of engineered T cells in pancreatic ductal adenocarcinoma (PDA). The findings suggest that blockade of PD-1 signaling alone is not enough to overcome the dysfunction of TCR engineered T cells in PDA. Contributions from both the differentiation pathways induced during the T cell engineering process and intratumoral suppressive mechanisms render engineered T cells dysfunctional.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Engineering, Biomedical
Michaela Petaroudi, Aleixandre Rodrigo-Navarro, Oana Dobre, Matthew J. Dalby, Manuel Salmeron-Sanchez
Summary: Living biointerfaces are a new type of biomaterials that combine living cells and polymeric matrices to act as instructive materials for surrounding cells. In this study, living biomaterials based on Lactococcus lactis expressing specific genes were used to control hematopoietic stem cells in both 2D and 3D environments. The results showed that these living biomaterials can direct the interaction between stem cells and bacteria, and can significantly expand the population of specific stem cells in 3D hydrogels. The findings suggest the potential of using genetically engineered bacteria-based living materials for ex-vivo expansion of stem cells and clinical applications in hematological disorders.
ADVANCED HEALTHCARE MATERIALS
(2022)
Article
Oncology
A. J. Robert McGray, Jessie L. Chiello, Takemasa Tsuji, Mark Long, Kathryn Maraszek, Nicole Gaulin, Spencer R. Rosario, Suzanne M. Hess, Scott Abrams, Danuta Kozbor, Kunle Odunsi, Emese Zsiros
Summary: The therapeutic efficacy of cancer immunotherapies in ovarian cancer is limited. Researchers have developed T cells that secrete a bispecific T-cell engager targeting the folate receptor alpha commonly overexpressed in OC. These T cells efficiently lyse tumor cells and induce antitumor immunity. Preconditioning of T cells with cytokines improves therapeutic efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)